Outpatient diuretic intensification: a simple prognostic marker in cardiac transthyretin amyloidosis
Authors:
Open Access
- 4 March 2025
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 115 (5) , 752-762
Abstract
Background: Currently, simple clinical parameters indicating disease progression are lacking in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate the prognostic value of outpatient diuretic intensification (ODI) in ATTR-CM patients. Methods: This retrospective study examined ATTR-CM patients at a tertiary care center between August 1, 2020, and June 30, 2023. ODI was defined as any loop diuretic increase within 6 months after baseline visit, and its impact on all-cause mortality and hospitalization for heart failure (HF) was analyzed. Results: Altogether, 182 patients were included (median age 80 [76; 84] years; 88% male), and 25% experienced ODI (median increase 10 [10; 40] mg furosemide equivalent). Independent predictors of ODI were higher baseline New York Heart Association (NYHA) class and polyneuropathy. Both any ODI and the magnitude of furosemide equivalent increase were significantly associated with mortality and HF hospitalization during a median follow-up of 17 months. After adjusting for baseline NYHA class and National Amyloidosis Centre stage, significantly increased risk of all-cause mortality (hazard ratio [HR] 2.38, 95% confidence interval [CI] 1.03–5.53; p = 0.043) and HF hospitalization (HR 3.27, 95% CI 1.41–7.60; p = 0.006) persisted in patients with ODI. Its prognostic value was similar in strata of age, ATTR subtype, previous cardiac decompensation, biomarkers, left ventricular ejection fraction, six-minute walk distance, and tafamidis treatment. Conclusion: ODI occurred in one in four ATTR-CM patients within 6 months and was associated with more severe baseline amyloid organ manifestations. ODI and the magnitude of diuretic dose increase provide easily assessable clinical markers of disease progression in patient monitoring. Graphical A total of 182 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR-CM) were analyzed for an increase in loop diuretic dosage within the first 6 months after the baseline visit. Twenty-five percent of the cohort experienced outpatient diuretic intensification (ODI), with independent predictors being dyspnea in higher New York Heart Association (NYHA) class and polyneuropathy (PNP). ODI was significantly associated with all-cause mortality, and its prognostic value remained consistent across various risk factorsKeywords
Funding Information
- Universitätsklinikum Köln
This publication has 30 references indexed in Scilit:
- Utility of Neuropathy Screening for Wild-Type Transthyretin Amyloidosis PatientsCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2020
- Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac AmyloidosisJACC: Cardiooncology, 2020
- Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac AmyloidosisJACC: Heart Failure, 2020
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2018
- A new staging system for cardiac transthyretin amyloidosisEuropean Heart Journal, 2017
- Frailty in Older Adults Undergoing Aortic Valve ReplacementJACC, 2017
- Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacementEuropean Heart Journal, 2017
- Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging SystemJACC, 2016
- Obesity and natriuretic peptides, BNP and NT-proBNP: Mechanisms and diagnostic implications for heart failureInternational Journal of Cardiology, 2014
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005